Search Result

Results for "

mTOR+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Akt (6) AMPK (2) Antibiotic (6) Apoptosis (21) Atg8/LC3 (1) Autophagy (28) Bacterial (7) Bcl-2 Family (1) Biochemical Assay Reagents (1) Caspase (1) CDK (1) Deubiquitinase (1) DNA-PK (6) Drug Derivative (2) Drug Intermediate (2) Drug Metabolite (1) Endogenous Metabolite (6) FKBP (7) Fungal (6) HDAC (2) HIF/HIF Prolyl-Hydroxylase (1) HSP (2) Isotope-Labeled Compounds (3) MDM-2/p53 (1) Mitochondrial Metabolism (1) Mitophagy (2) MMP (1) mTOR (107) nAChR (1) P-glycoprotein (1) p38 MAPK (1) Paraptosis (1) Parasite (2) PI3K (54) Reactive Oxygen Species (ROS) (1) Reference Standards (9) Ribosomal S6 Kinase (RSK) (2) STAT (1) STING (1) VEGFR (1) Xanthine Oxidase (2)
By Research Areas:	Cancer (103) Cardiovascular Disease (2) Infection (7) Inflammation/Immunology (9) Metabolic Disease (7) Neurological Disease (10)
Click Chemistry:	Azide (1)

114

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10219

Rapamycin 1335+ Cited Publications Sirolimus; AY-22989; NSC 226080	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-13002

Torin 2 15+ Cited Publications	mTOR DNA-PK Autophagy Apoptosis	Cancer
Torin 2 is an *mTOR* inhibitor with EC₅₀ of 0.25 nM for inhibiting cellular mTOR activity, and exhibits 800-fold selectivity over PI3K (EC₅₀: 200 nM). Torin 2 also inhibits DNA-PK with an IC₅₀ of 0.5 nM in the cell free assay. Torin 2 can suppress both mTORC1 and mTORC2.

HY-10115

PI-103 30+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 is a potent PI3K and *mTOR* inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy .

HY-111373

RapaLink-1 10+ Cited Publications	mTOR Autophagy	Cancer
RapaLink-1, the third-generation bivalent *mTOR* inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .

HY-15247

Vistusertib 30+ Cited Publications AZD2014	mTOR Autophagy Apoptosis	Cancer
Vistusertib (AZD2014) is an ATP competitive *mTOR* inhibitor with an IC₅₀ of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.

HY-10474

Torkinib 25+ Cited Publications PP 242	mTOR Autophagy Mitophagy Apoptosis	Cancer
Torkinib (PP 242) is a selective and ATP-competitive *mTOR* inhibitor with an IC₅₀ of 8 nM . PP242 inhibits both mTORC1 and mTORC2 with IC₅₀s of 30 nM and 58 nM, respectively .

HY-12868

Bimiralisib 4 Publications Verification PQR309	PI3K mTOR	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I *PI3K/mTOR** inhibitor* with IC₅₀s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and *mTOR, respectively. Bimiralisib is an mTORC1* and mTORC2 inhibitor.

HY-50908

Ridaforolimus 10+ Cited Publications MK-8669; Deforolimus; AP23573	mTOR Autophagy Bacterial	Cancer
Ridaforolimus (MK-8669) is a potent and selective *mTOR* inhibitor; inhibits ribosomal protein S6 phosphorylation with an IC₅₀ of 0.2 nM in HT-1080 cells .

HY-50710

KU-0063794 10+ Cited Publications	mTOR	Cancer
KU-0063794 is a potent and specific *mTOR* inhibitor, inhibiting both the mTORC1 and mTORC2 complexes with IC₅₀s of 10 nM.

HY-14774

Monepantel 1 Publications Verification AAD1566; NUZ-001	mTOR Parasite nAChR Autophagy	Infection Neurological Disease Cancer
Monepantel (AAD1566, NUZ-001), an antiparasitic agent, is an orally active *mTOR* inhibitor. Monepantel triggers autophagy through the deactivation of mTOR/p70S6K signalling pathway. Monepantel is a positive allosteric modulator of a nematode-specific clade of nAChR subunits. Monepantel can be used for the study of amyotrophic lateral sclerosis (ALS) and ovarian cancer .

HY-111508

*PI3K/mTOR Inhibitor-2* 1 Publications Verification	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR* inhibitor* with IC₅₀s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for *mTOR* . Antitumor activity .

HY-13806

XL388 4 Publications Verification	mTOR Autophagy	Cancer
XL388 is a highly potent and ATP-competitive *mTOR* inhibitor with an IC₅₀ of 9.9 nM. XL388 simultaneously inhibits both mTORC1 and mTORC2.

HY-136660

PQR626	mTOR	Neurological Disease
PQR626, a rapamycin derivative, is a potent, selective, orally active, and brain-penetrant *mTOR* inhibitor, with an IC₅₀ and K_i of 5 nM and 3.6 nM, respectively. PQR626 can be can be used for the research of neurological disorders .

HY-112914

mTOR inhibitor-1 3 Publications Verification	mTOR Autophagy	Cancer
mTOR inhibitor-1 (Compound C-4) is an ATP-Competitive *mTOR* inhibitor which can suppress cells proliferation and inducing autophagy .

HY-10115A

PI-103 Hydrochloride 30+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 Hydrochloride is a dual PI3K and *mTOR* inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy .

HY-100222

CZ415 4 Publications Verification	mTOR	Cancer
CZ415 is a potent and highly selective *mTOR* inhibitor with a pIC₅₀ of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex.

HY-15248

GDC-0349 2 Publications Verification	mTOR Autophagy	Cancer
GDC-0349 is a potent and selective ATP-competitive *mTOR* inhibitor with a K_i of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes.

HY-10219S

Rapamycin-d3 1 Publications Verification Sirolimus-d₃; AY-22989-d₃; NSC 226080-d₃	Isotope-Labeled Compounds mTOR FKBP Autophagy	Cancer
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-18353

mTOR inhibitor-3 3 Publications Verification	mTOR	Cancer
mTOR inhibitor-3 is a remarkably selective *mTOR* inhibitor with a K_i of 1.5 nM. mTOR inhibitor-3 suppresses mTORC1 and mTORC2 in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.

HY-10219R

Rapamycin (Standard) Sirolimus (Standard); AY-22989 (Standard); NSC 226080 (Standard)	Reference Standards mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Cancer
Rapamycin (Standard) is the analytical standard of Rapamycin (HY-10219). This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-10811

GNE-493 2 Publications Verification	PI3K mTOR	Cancer
GNE-493 is a potent, selective, and orally available dual *pan-PI3-kinase/mTOR** inhibitor* with IC₅₀s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.

HY-12034

WYE-354 5+ Cited Publications	mTOR Autophagy Apoptosis	Cancer
WYE-354 is an ATP-competitive *mTOR* inhibitor with an IC₅₀ of 5 nM. WYE-354 also inhibits PI3Kα and PI3Kγ with IC₅₀s of 1.89 μM and 7.37 μM, respectively. WYE-354 inhibits both mTORC1 and mTORC2. WYE-354 induces autophagy activation in vitro .

HY-114414

*HDACs/mTOR Inhibitor* 1** 1 Publications Verification	HDAC mTOR Apoptosis	Cancer
HDACs/mTOR Inhibitor 1 is a dual HDACs and mTOR inhibitor, with IC₅₀s of 0.19 nM, 1.8 nM, 1.2 nM for HDAC1, HDAC6, mTOR, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induces tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1 can be used in the research of hematologic malignancies .

HY-12763

GNE-317 2 Publications Verification	PI3K mTOR	Cancer
GNE-317 is a *PI3K/mTOR** inhibitor*, is able to cross the blood-brain barrier (BBB).

HY-12424A

42-(2-Tetrazolyl)rapamycin	Drug Intermediate	Cancer
42-(2-Tetrazolyl)rapamycin is a proagent compound of a rapamycin analog extracted from patent US 20080171763 A1, Example 1. Rapamycin is a specific mTOR inhibitor.

HY-15272

WAY-600 5+ Cited Publications	mTOR	Inflammation/Immunology Cancer
WAY-600 is a potent, ATP-competitive, and selective *mTOR* inhibitor with an IC₅₀ of 9 nM for recombinant mTOR enzyme. WAY-600 blocks mTOR complex 1/2 (mTORC1/2) assemble and activation.

HY-15271

WYE-687 3 Publications Verification	mTOR PI3K	Cancer
WYE-687 is an ATP-competitive *mTOR* inhibitor with an IC₅₀ of 7 nM. WYE-687 concurrently inhibits activation of mTORC1 and mTORC2. WYE-687 also inhibits PI3Kα and PI3Kγ with IC₅₀s of 81 nM and 3.11 μM, respectively.

HY-158039

YCH2823	Deubiquitinase Apoptosis	Cancer
YCH2823 is an inhibitor of USP7 (IC₅₀ = 49.6 nM; K_d = 0.117 μM). YCH2823 shows significant efficacy in inhibiting TP53 wild-type and mutant tumors, with approximately 5-fold higher potency than FT671. YCH2823 induce apoptosis. YCH2823 synergistic effects with mTOR inhibitors .

HY-10219S1

Rapamycin-13C,d3 Sirolimus-¹³C,d₃; AY-22989-¹³C,d₃ NSC 226080-¹³C,d₃	Isotope-Labeled Compounds mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Cancer
Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) . Rapamycin is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219G

Rapamycin Sirolimus; AY-22989; NSC 226080	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Infection Cancer
Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219GL

Rapamycin (GMP Like) Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Cancer
Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-151622

*PI3K/mTOR Inhibitor-11* 2 Publications Verification	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-11 is an orally active *PI3K/mTOR* inhibitor (IC₅₀: 3.5, 4.6, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR). PI3K/mTOR Inhibitor-11 regulates the PI3K/AKT/mTOR signaling pathway by inhibiting the phosphorylation of AKT and S6 proteins. PI3K/mTOR Inhibitor-11 can be used in the research of cancers .

HY-118712

WYE-23	mTOR	Cancer
WYE-23 is a *mTOR* inhibitor, and IC₅₀ is 0.45 nM. It is selective to PI3Kα and IC₅₀ is 661 nM. WYE-23 has antitumor activity .

HY-124036

DS-7423	PI3K mTOR	Cancer
DS-7423 is a dual PI3K and *mTOR* inhibitor, with IC₅₀ values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity .

HY-131344

mTOR inhibitor-8	mTOR Autophagy	Cancer
mTOR inhibitor-8 is an *mTOR* inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells .

HY-134903

(32-Carbonyl)-RMC-5552	mTOR	Cancer
(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC₅₀s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2) .

HY-128333

*PI3K/mTOR Inhibitor-4*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-4 is an orally active pan-class I *PI3K/mTOR* inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC₅₀ values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer .

HY-153120A

*PI3K/mTOR Inhibitor-13 sodium*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and *mTOR* kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-100470

NSC781406 2 Publications Verification	PI3K mTOR	Cancer
NSC781406 is a highly potent PI3K and *mTOR* inhibitor with an IC₅₀ of 2 nM for PI3Kα.

HY-136583

28-Epirapamycin	Drug Metabolite	Others
28-Epirapamycin is an impurity of Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells .

HY-118717

mTOR inhibitor WYE-28	mTOR	Cancer
mTOR inhibitor WYE-28 (compound 28) is a selective inhibitor of mTOR>/b< (IC₅₀)=0.08 nM. mTOR inhibitor WYE-28 inhibits PI3Kα with an IC50 value of 6 nM. mTOR inhibitor WYE-28 shows a metabolic time (T_1/2) in nude mouse microsomes of 13 min .

HY-141805

MHY-1685	mTOR	Cancer
MHY-1685, a novel mammalian target of rapamycin *(mTOR)* inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.

HY-15247R

Vistusertib (Standard) AZD2014 (Standard)	mTOR Autophagy Apoptosis Reference Standards	Cancer
Vistusertib (Standard) is the analytical standard of Vistusertib. This product is intended for research and analytical applications. Vistusertib (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.

HY-50673A

Dactolisib hydrochloride 60+ Cited Publications BEZ235 hydrochloride; NVP-BEZ235 hydrochloride	PI3K mTOR Autophagy	Cancer
Dactolisib (BEZ235) hydrochloride is an orally active, dual pan-class I PI3K and mTOR inhibitor for p110α/γ/δ/β and *mTOR* with IC₅₀ of 4 nM/5 nM/7 nM/75 nM and 20.7 nM, respectively. Dactolisib hydrochloride (BEZ235) inhibits mTORC1 and mTORC2 .

HY-153120

*PI3K/mTOR Inhibitor-13*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and *mTOR* kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-15269

PP30	mTOR Akt PI3K	Cancer
PP30 is a potent, selective, ATP-competitive *mTOR* inhibitor with an IC₅₀ of 80 nM. PP30 blocks insulin-stimulated phosphorylation of Akt at residues S473 and T308, preventing the full activation of Akt. PP30 is applicable for cancer research .

HY-155211

mTOR inhibitor-13	mTOR PI3K	Cancer
mTOR inhibitor-13 (compound 9g), an aryl ureido compound, is a potent and selective *mTOR* inhibitor with an IC₅₀ of 0.29 nM. mTOR inhibitor-13 also inhibits PI3K-α with an IC₅₀ of 119 nM .

HY-123849

SN32976	PI3K mTOR	Cancer
SN32976 is a potent and selective class I PI3K and *mTOR* inhibitor with IC₅₀s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and *mTOR*, respectively. SN32976 shows high selectivity among other 442 kinases. SN32976 shows anticancer effects .

HY-178431

MT-44	mTOR Apoptosis Reactive Oxygen Species (ROS) STING	Cancer
MT-44 is a highly selective and potent *mTOR* inhibitor with an IC₅₀ of 49.4 nM. MT-44 can inhibit cancer cells proliferation, migration and invasion. MT-44 can induce cells apoptosis and ROS production and cause G2/M phase arrest. MT-44 can activate the cGAS/STING pathway. MT-44 can be used for the research of cancer, such as triple-negative breast cancer .

HY-112602

*PI3K/mTOR Inhibitor-1*	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual *PI3K/mTOR** inhibitor* with IC₅₀s of 20/376/204/46 nM and 186 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ and *mTOR*, respectively . Antitumor activity .

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library

1,049 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 1,049 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Type

HY-10219G

Rapamycin

Sirolimus; AY-22989; NSC 226080

Fluorescent Dyes

Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219GL

Rapamycin (GMP Like)

Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)

Fluorescent Dyes

Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

Cat. No.	Product Name	Type

HY-10219G

Rapamycin

Sirolimus; AY-22989; NSC 226080

Biochemical Assay Reagents

HY-10219GL

Rapamycin (GMP Like)

Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10219

Rapamycin 1335+ Cited Publications Sirolimus; AY-22989; NSC 226080	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Anti-aging Disease Research Disease Research Fields Source Classification Cancer	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219R

Rapamycin (Standard) Sirolimus (Standard); AY-22989 (Standard); NSC 226080 (Standard)	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Antibiotics Disease Research Endogenous metabolite Source Classification	Reference Standards mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Standard) is the analytical standard of Rapamycin (HY-10219). This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-Y0106

2,6-Dihydroxyacetophenone	Classification of Application Fields Ketones, Aldehydes, Acids Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	mTOR Xanthine Oxidase Apoptosis
2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active *mTOR* inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .

HY-Y0106R

2,6-Dihydroxyacetophenone (Standard)	Structural Classification Ketones, Aldehydes, Acids Phenols Polyphenols Endogenous metabolite Source Classification	Reference Standards mTOR Xanthine Oxidase Apoptosis
2,6-Dihydroxyacetophenone (Standard) is the analytical standard of 2,6-Dihydroxyacetophenone (HY-Y0106). This product is intended for research and analytical applications. 2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active *mTOR* inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .

Cat. No.	Product Name	Chemical Structure

HY-10219S

Rapamycin-d3 1 Publications Verification
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219S1

Rapamycin-13C,d3
Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) . Rapamycin is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-W765245

Rapamycin-13C,d3-1
Rapamycin- ¹³C,d₃-1 (Sirolimus- ¹³C,d₃-1) is the deuterium labeled and ¹³C-labeled Rapamycin (HY-10219). Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

Cat. No.	Product Name		Classification

HY-176947

Demethyl-sapanisertib-C2-amide-PEG7-C2-N3		Azide
Demethyl-sapanisertib-C2-amide-PEG7-C2-N3 (Compound 10c) is an azide group linker used for coupling, which can be employed in the synthesis of "Rapa-Link" compounds, such as M-1111 (HY-176948), an mTOR inhibitor .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10219G

Rapamycin Sirolimus; AY-22989; NSC 226080	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Infection Cancer
Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific *mTOR* inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

mTOR+inhibitor

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Natural
Products